ArticleHepatology (Baltimore, Md.)2021
Early Cholangiocarcinoma Detection With Magnetic Resonance Imaging Versus Ultrasound in Primary Sclerosing Cholangitis.
Article in Hepatology (Baltimore, Md.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Gallbladder neoplasia is associated with a higher incidence of cholangiocarcinoma in patients with primary sclerosing cholangitis.Canadian liver journal · 2026Article
- MR imaging and cholangiography show suboptimal performance for diagnosing ductal cholangiocarcinoma in primary sclerosing cholangitis patients.European radiology · 2025Article
- Ultrasound for the Detection of Gallbladder Malignancy in Primary Sclerosing Cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Benign biliary conditions with increased risk of malignant lesions.Abdominal radiology (New York) · 2025Review
- Artificial Intelligence and Radiomics in Cholangiocarcinoma: A Comprehensive Review.Diagnostics (Basel, Switzerland) · 2025Review
- Surveillance MRI is associated with improved survival in patients with primary sclerosing cholangitis.Hepatology communications · 2024Article
- Application of AI on cholangiocarcinoma.Frontiers in oncology · 2024Review
- Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma: From Pathogenesis to Diagnostic and Surveillance Strategies.Cancers · 2023Review
- Review
- Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.Journal of hepatology · 2023Article
- Surveillance for cholangiocarcinoma in patients with primary sclerosing cholangitis: Can we be more proactive?Frontline gastroenterology · 2023Article
- Primary sclerosing cholangitis: review for radiologists.Abdominal radiology (New York) · 2023Review
- Impact on follow-up strategies in patients with primary sclerosing cholangitis.Liver international : official journal of the International Association for the Study of the Liver · 2023Article
- Hepatobiliary manifestations in inflammatory bowel disease: A practical approach.World journal of hepatology · 2022Review
- Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group.European radiology · 2022Article
- Comparative Performance of Quantitative and Qualitative Magnetic Resonance Imaging Metrics in Primary Sclerosing Cholangitis.Gastro hep advances · 2022Article
- Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile.Hepatology (Baltimore, Md.) · 2022Observational
- Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers.Frontiers in oncology · 2022Review
- Cholangiocarcinoma.Nature reviews. Disease primers · 2021Review
- Progress toward improving outcomes in patients with cholangiocarcinoma.Current treatment options in gastroenterology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsEarly detection of perihilar cholangiocarcinoma (CCA) among patients with primary sclerosing cholangitis (PSC) is important to identify more people eligible for curative therapy. While many recommend CCA screening, there are divergent opinions and limited data regarding the use of ultrasound or magnetic resonance imaging (MRI) for early CCA detection, and it is unknown whether there is benefit in testing asymptomatic individuals. Our aims were to assess the diagnostic performances and prognostic implications of ultrasound and MRI-based CCA detection. APPROACH AND
resultsThis is a multicenter review of 266 adults with PSC (CCA, n = 120) who underwent both an ultrasound and MRI within 3 months. Images were re-examined by radiologists who were blinded to the clinical information. Respectively, MRI had a higher area under the curve compared with ultrasound for CCA detection: 0.87 versus 0.70 for the entire cohort; 0.81 versus 0.59 for asymptomatic individuals; and 0.88 versus 0.71 for those listed for CCA transplant protocol. The absence of symptoms at CCA diagnosis was associated with improved 5-year outcomes including overall survival (82% vs. 46%, log-rank P < 0.01) and recurrence-free survival following liver transplant (89% vs. 65%, log-rank P = 0.04). Among those with asymptomatic CCA, MRI detection (compared with ultrasound) was associated with reduction in both mortality (hazard ratio, 0.10; 95% confidence interval, 0.01-0.96) and CCA progression after transplant listing (hazard ratio, 0.10; 95% confidence interval, 0.01-0.90). These benefits continued among patients who had annual monitoring and PSC for more than 1 year before CCA was diagnosed.
conclusionsMRI is superior to ultrasound for the detection of early-stage CCA in patients with PSC. Identification of CCA before the onset of symptoms with MRI is associated with improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.